Low levels of ADAMTS‐13 with high anti‐ADAMTS‐13 antibodies during remission of immune‐mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi‐institutional study
- 29 April 2020
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 95 (8), 953-959
- https://doi.org/10.1002/ajh.25845
Abstract
Immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is a life‐threatening immune‐mediated thrombotic microangiopathy. Daily therapeutic plasma exchange (TPE) and the optimized use of rituximab have strikingly improved the outcome of this disease, however the rate of disease recurrence remains high. Specific predictors of relapse in patients in remission can be relevant for an optimal patient management. In this study, we aimed to identify predictive variables of disease relapse in a multicenter cohort of 74 out of 153 iTTP patients, who were serially tested during remission for the levels of ADAMTS‐13 activity and autoantibody, and did not receive pre‐emptive treatment for ADAMTS‐13 activity deficiency during remission. The results showed that the association of ADAMTS13 activity ≤20% with a high anti‐ADAMTS‐13 titer at remission, and the time to response to first line treatment ≥13 days, were independent predictive factors of disease relapse. In addition, the use of rituximab in patients with exacerbation or refractoriness to TPE was significantly associated with reduced relapse rate. By Cox regression analysis, patients with ADAMTS‐13 activity ≤20% plus anti‐ADAMTS13 antibody titer ≥15 U/mL at remission had an increased risk of relapse (HR 1.98, CI 95% 1.087‐3.614; p < 0.02). These findings may help to outline more personalized therapeutic strategies in order to provide faster and sustained responses to first‐line iTTP treatment and prevent relapses in these patients.This publication has 20 references indexed in Scilit:
- Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapseJournal of Thrombosis and Haemostasis, 2012
- Survival and relapse in patients with thrombotic thrombocytopenic purpuraBlood, 2010
- Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapseBritish Journal of Haematology, 2008
- ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remissionHaematologica, 2008
- Rituximab as preventive therapy of a clinical relapse in TTP with ADAMTS13 inhibitorAmerican Journal of Hematology, 2007
- Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activityBlood, 2006
- Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 casesBlood, 2005
- Thrombotic MicroangiopathiesThe New England Journal of Medicine, 2002
- Late Relapses in Patients Successfully Treated for Thrombotic Thrombocytopenic PurpuraAnnals of Internal Medicine, 1995
- Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic PurpuraThe New England Journal of Medicine, 1991